History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report

Minlikeeva, Albina N.; Freudenheim, Jo L.; Cannioto, Rikki A.; Eng, Kevin H.; Szender, J. Brian; Mayor, Paul; Etter, John Lewis; Cramer, Daniel W.; Diergaarde, Brenda; Doherty, Jennifer A.; Dörk, Thilo; Edwards, Robert P.; deFazio, Anna; Friel, Grace; Goodman, Marc T.; Hillemanns, Peter; Høgdall, Estrid; Jensen, Allan; Jordan, Susan J.; Karlan, Beth Y.; Kjær, Susanne K.; Klapdor, R; Matsuo, Keitaro; Mizuno, Mika; Nagle, Christina M.; Odunsi, Kunle; Paddock, Lisa E.; Rossing, Mary Anne; Schildkraut, Joellen M.; Schmalfeldt, Barbara; Segal, Brahm H.; Starbuck, Kristen; Terry, Kathryn L.; Webb, Penelope M.; Zsiros, Emese; Ness, Roberta B.; Modugno, Francesmary; Bandera, Elisa V.; Chang‐Claude, Jenny; Moysich, Kirsten B.

doi:10.1038/bjc.2017.267

Cited by 18 publications

(15 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, other epidemiological studies e.g. in patients with ovarian cancer reported conflicting results suggesting that hyperthyroidism and overall history of hypothyroidism are associated with worse 5-year survival [11]. A case report of a patient suffering from metastatic nonesmall-cell lung cancer surviving a myxoedema coma and subsequent stabilization of cancer progression for more than 5 years, was the basis for clinical attempts to interfere with TH signalling in patients with cancer [12].…”

Section: Discussionmentioning

confidence: 99%

Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer

Berghoff

Wippel

Starzer

et al. 2020

European Journal of Cancer

View full text Add to dashboard Cite

Background: Several preclinical and epidemiologic studies have indicated tumourpromoting effects of thyroid hormones (THs). However, very limited knowledge exists on the prognostic impact of thyroid function in metastatic cancer. Methods: We compiled a discovery cohort of 1692 patients with newly diagnosed brain metastases (BMs) of solid cancers treated at the Medical University of Vienna and an independent validation cohort of 191 patients with newly diagnosed BMs treated at the University Hospital Zurich. Results: Hypothyroidism before diagnosis of cancer was evident in 133 of 1692 (7.9%) patients of the discovery, and in 18 of 191 (9.4%) patients of the validation cohort. In the discovery cohort, hypothyroidism was statistically significantly associated with favourable survival

show abstract

Section: Discussionmentioning

confidence: 99%

Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer

Berghoff

Wippel

Starzer

et al. 2020

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…A large demographic study, the "Ovarian Cancer Association Consortium", showed that hyperthyroidism within the 5 years before ovarian cancer diagnosis was associated with an increased risk of death (Minlikeeva et al 2017). These very recent results were accompanied by the fact that a more modest association was observed with the history of hypothyroidism (n = 624 cases) and mortality (Minlikeeva et al 2017).…”

Section: Discussionmentioning

confidence: 99%

Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients

Ditsch

Heublein

Jeschke

et al. 2020

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose Thyroid hormone receptors (THR) have manifold functions and are involved in the carcinogenesis of several tumor types. Within this study, we aimed to investigate the expression pattern (nuclear versus cytoplasmic) of the THR alpha and its impact on patients survival in ovarian cancer (OvCa). Methods The presence of the thyroid hormone receptors THRα, THRα1 and − 2 was investigated in 156 ovarian cancer samples using immunohistochemistry (IHC) using semi-quantitative immunoreactivity (IR) scores and correlated with clinical, pathological data, subtype of ovarian cancer, clinical data, staining of 20 already described OvCa marker proteins and overall survival (OS). Results Among all subtypes of OvCa, clear cell carcinomas showed the highest THRα expression. Furthermore, nuclear THRα was associated with a reduced survival in this subtype. However, nuclear expressed THRα1 turned out to be a positive prognosticator for all subtypes of OvCa patients. Nuclear THRα2 is a positive prognosticator for OvCa patients of the serous subtype. In contrast, cytoplasmic expression THRα2 was associated with a reduced OS in all subtypes of OvCa patients; while, cytoplasmic expression of THRα1 is associated with reduced OS in mucinous OvCa patients only. In addition, THRα expression correlates with gonadotropin receptors, steroid hormone receptors, TA-MUC1 and glycodelin. Conclusion Depending on nuclear or cytoplasmic expression, our study shows that THRα and its isoforms 1 and 2 provide different prognostic information for ovarian cancer patients. Further investigations should analyze if THRs may represent new endocrine targets for the treatment of ovarian cancer.

show abstract

“…Minlikeeva et al used collective data from 11 studies, including information on thyroid hormone status for a total of 5,822 patients diagnosed with invasive ovarian cancer (163). Increased risk of mortality was demonstrated for patients with a history of hyperthyroidism in the 5 years preceding cancer diagnosis (HR = 1.94; p = 0.01).…”

Section: Clinical Studies Of the Thyroid-cancer Associationmentioning

confidence: 99%

Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies

Krashin¹,

Piekiełko-Witkowska²,

Ellis³

et al. 2019

Front. Endocrinol.

159

105

View full text Add to dashboard Cite

Thyroid hormones take major part in normal growth, development and metabolism. Over a century of research has supported a relationship between thyroid hormones and the pathophysiology of various cancer types. In vitro studies as well as research in animal models demonstrated an effect of the thyroid hormones T3 and T4 on cancer proliferation, apoptosis, invasiveness and angiogenesis. Thyroid hormones mediate their effects on the cancer cell through several non-genomic pathways including activation of the plasma membrane receptor integrin αvβ3. Furthermore, cancer development and progression are affected by dysregulation of local bioavailability of thyroid hormones. Case-control and population-based studies provide conflicting results regarding the association between thyroid hormones and cancer. However, a large body of evidence suggests that subclinical and clinical hyperthyroidism increase the risk of several solid malignancies while hypothyroidism may reduce aggressiveness or delay the onset of cancer. Additional support is provided from studies in which dysregulation of the thyroid hormone axis secondary to cancer treatment or thyroid hormone supplementation was shown to affect cancer outcomes. Recent preclinical and clinical studies in various cancer types have further shown promising outcomes following chemical reduction of thyroid hormones or inhibition or their binding to the integrin receptor. This review provides a comprehensive overview of the preclinical and clinical research conducted so far.

show abstract

History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report

Cited by 18 publications

References 32 publications

Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer

Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer

Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients

Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies

Contact Info

Product

Resources

About